Elevance Health is reaffirming full-year 2026 shareholders’ Earnings guidance of at least $20.10 per diluted share, including approximately $6.90 per diluted share of net unfavorable items. The company’s outlook gives investors stated targets for adjusted earnings and the benefit expense ratio as management meets with analysts.
Key Highlights
- Adjusted shareholders’ earnings guidance remains at least $27.00 per diluted share for full year 2026.
- Elevance Health reaffirmed full-year 2026 shareholders’ earnings guidance of at least $20.10 per diluted share.
- The outlook is subject to risks including healthcare cost trends, enrollment changes, regulatory developments, Cybersecurity incidents and competitive pressures.
Elevance Health, Inc. (NYSE: ELV) is reaffirming full-year 2026 shareholders’ earnings guidance of at least $20.10 per diluted share.
Adjusted Earnings and Cost Ratio Targets
The guidance applies to full year 2026. Elevance Health said the outlook excludes adjustment items beyond those reported in its second quarter 2026 earnings. Benefit expense ratio guidance remains 90.2%, with a range of plus or minus 50 basis points.
Forward-Looking Guidance Carries Stated Risks
The earnings and benefit expense targets are forward-looking statements, and Elevance Health cautioned that actual financial performance may differ from those projections. The company identified healthcare cost and utilization trends, enrollment changes, premium-rate sufficiency and changes in healthcare, insurance and pharmacy regulations among the uncertainties affecting its outlook. Risks also include cybersecurity incidents, information-system failures, Medicare and Medicaid developments, provider contracting and competitive pressures. Elevance Health advised investors not to place undue reliance on the projections and said it does not undertake to update them except where required by law.
FAQs
Q: What is Elevance Health’s 2026 earnings guidance?
A: Elevance Health is reaffirming full-year 2026 shareholders’ earnings guidance of at least $20.10 per diluted share. The guidance applies to full year 2026 and excludes adjustment items beyond those reported in its second quarter 2026 earnings.
Q: What is Elevance Health’s 2026 benefit expense ratio target?
A: Elevance Health reaffirmed full-year 2026 benefit expense ratio guidance of 90.2%. The stated range is plus or minus 50 basis points.
Q: What are Elevance Health’s adjusted earnings expectations?
A: Elevance Health expects adjusted shareholders’ earnings of at least $27.00 per diluted share for full year 2026. That measure excludes the specified net unfavorable items.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.